ADMA Biologics Inc (ADMA)
Profitability ratios
Return on sales
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit margin | 51.48% | 48.93% | 46.12% | 39.39% | 34.44% | 30.74% | 27.41% | 26.45% | 22.89% | 18.85% | 13.92% | 6.97% | 1.45% | -10.94% | -16.28% | -29.47% | -45.17% | -33.67% | -34.06% | -30.28% |
| Operating profit margin | 32.59% | 30.01% | 25.42% | 15.63% | 8.38% | 0.57% | -8.01% | -13.94% | -25.55% | -35.64% | -46.89% | -61.73% | -72.12% | -91.08% | -106.29% | -131.70% | -153.75% | -137.77% | -136.31% | -124.89% |
| Pretax margin | 29.48% | 19.16% | 11.86% | -1.08% | -10.94% | -9.74% | -19.36% | -26.22% | -42.77% | -53.89% | -66.44% | -83.27% | -88.51% | -108.59% | -126.67% | -155.78% | -179.41% | -166.00% | -164.90% | -151.18% |
| Net profit margin | 46.35% | 17.80% | 10.53% | -1.29% | -10.94% | -9.74% | -19.36% | -26.22% | -42.77% | -53.89% | -66.44% | -83.27% | -88.51% | -108.59% | -126.67% | -155.78% | -179.41% | -166.00% | -164.90% | -151.18% |
ADMA Biologics Inc has shown a significant improvement in its profitability ratios over the past few years. The Gross Profit Margin, which signifies the percentage of revenue remaining after subtracting the cost of goods sold, has shown a consistent increase from negative values to exceeding 50% by December 31, 2024. This improvement indicates stronger pricing power and cost management.
The Operating Profit Margin, which indicates the company's ability to generate profits from its core operations, has also shown a positive trend, improving from negative values to over 30% by December 31, 2024. This suggests better control over operating expenses and more efficient operations.
The Pretax Margin, reflecting the company's earnings before taxes as a percentage of total revenue, has also improved significantly over the years, moving from deeply negative values to around 30% by December 31, 2024. This improvement highlights the company's ability to generate profits before tax implications and improve overall financial performance.
Lastly, the Net Profit Margin, which represents the percentage of revenue that translates into net income, has shown a remarkable turnaround from negative values to over 46% by December 31, 2024. This increase demonstrates the company's ability to generate more profit from its revenue after accounting for all expenses and taxes.
Overall, the strong improvements across all profitability ratios indicate a positive financial performance trajectory for ADMA Biologics Inc, showcasing enhanced operational efficiency and financial management.
Return on investment
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | 28.44% | 29.41% | 22.30% | 12.62% | 6.57% | 0.38% | -4.86% | -7.44% | -11.30% | -15.47% | -17.38% | -18.84% | -21.13% | -26.15% | -26.53% | -26.86% | -31.26% | -29.23% | -26.51% | -21.37% |
| Return on assets (ROA) | 40.45% | 17.44% | 9.24% | -1.04% | -8.58% | -6.54% | -11.75% | -13.99% | -18.91% | -23.40% | -24.63% | -25.41% | -25.94% | -31.18% | -31.62% | -31.77% | -36.47% | -35.22% | -32.07% | -25.87% |
| Return on total capital | 33.07% | 34.58% | 26.39% | 15.68% | 8.14% | 0.46% | -5.80% | -8.75% | -13.35% | -19.23% | -20.31% | -21.87% | -24.73% | -31.65% | -30.06% | -30.74% | -35.82% | -32.97% | -29.27% | -23.37% |
| Return on equity (ROE) | 56.64% | 29.38% | 18.48% | -2.37% | -20.89% | -15.07% | -27.45% | -32.74% | -43.37% | -70.05% | -63.93% | -61.67% | -50.75% | -72.39% | -65.96% | -66.56% | -85.83% | -93.73% | -79.89% | -56.53% |
ADMA Biologics Inc's profitability ratios have shown a significant improvement over the years, indicating a positive trend in the company's profitability.
- Operating Return on Assets (Operating ROA) was negative in the earlier periods, but steadily improved from -21.37% in March 2020 to 28.44% in December 2024. This suggests that the company became more efficient in generating profits from its operating assets.
- Return on Assets (ROA) also followed a similar trend, improving from -25.87% in March 2020 to 40.45% in December 2024. This indicates that the company's overall asset utilization and profitability increased over the years.
- Return on Total Capital showed a consistent improvement from negative values in earlier periods to 33.07% in December 2024. This indicates that the company was able to generate better returns for its total invested capital.
- Return on Equity (ROE) presented a similar trend, with negative values in the beginning, but gradually improving to 56.64% in December 2024. This indicates that the company was able to deliver increasing returns to its equity shareholders over the years.
Overall, the improving trend in profitability ratios suggests that ADMA Biologics Inc has been successful in enhancing its profitability, asset utilization, and returns to both operating and equity capital providers.